TGFB1 and Myocardial fibrosis: Thus, empagliflozin reduces the severity of oxidative stress by activation of the Nrf2/ARE signalling pathway and reduces myocardial fibrosis by inhibiting the TGF-Beta1/Smad3 signalling pathway.